575 Results (Page 20 of 23)
China Markets Research Reports
China Connected Healthcare Market Analysis
The China-connected healthcare market is projected to grow from $5.34 Bn in 2022 to $43.25 Bn by 2030, registering a CAGR of 29.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be a large and ageing population, government support, technological advancements and a rising middle class. The market is segmented by type, function and by application. Some of the major players include Tencent Health, JD Health International, WeDoctor, iCarbonX, Roche, GE Healthcare and Medtronic.
China Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the China Oncology Therapeutics Market will reach a value of $31.1 Bn from $14.6 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030. The Oncology Therapeutics Market in China is dominated by a few domestic pharmaceutical companies such as Bristol Myers Squibb, Boehringer Ingelheim, and CureVac. The Oncology Therapeutics Market in China is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for China Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
China Biomaterials in Healthcare Market Analysis
The China Biomaterials Healthcare Market is expected to witness growth from $12.56 Bn in 2022 to $37.62 Bn in 2030 with a CAGR of 14.70% for the forecasted year 2022-2030. One of the world's biggest ageing populations is found in China. Medical implants and devices made of biomaterials are in greater demand as the population ages in China. The market is segmented by type and by application. Some key players in this market include Weigao Group, Suzhou Sinomed, MicroPort, BASF SE, Celanese, Covestro AG and Evonik Industries.
China Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the China liver cancer therapeutics market will reach a value of $953.6 Mn from $235.5 Mn in 2022, growing at a CAGR of 19.1% during 2022-30. The liver cancer therapeutics market in China is dominated by a few domestic pharmaceutical companies such as BeiGene, Chi-Med, and Jiangsu HengRui Medicine. The liver cancer therapeutics market in China is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
China Lung Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the China Lung Cancer Therapeutics Market will reach a value of $5 Bn from $2.4 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Lung Cancer Therapeutics Market in China is dominated by a few domestic pharmaceutical companies such as BeiGene, Jiangsu Hengrui Medicine, and Hutchison. The Lung Cancer Therapeutics Market in China is segmented into different types of cancer and different therapy type. Some of the major factors affecting the China lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.
China Diabetes Devices Market Analysis
The China Diabetes Devices Market is expected to grow from $1.82 Bn in 2022 to $3.56 Bn in 2030 with a CAGR of 8.70% for the forecasted year 2022-2030. Diabetes is a common condition in China, where the demand for diabetes-related products and devices is rising. The prevalence of diabetes is anticipated to increase as the population ages and urbanizes, providing significant opportunities for diabetes device manufacturers. The market is segmented by type and by the end user. Some key players in this market include Lepu Medical Technology, MicroPort, Johnson & Johnson, Medtronic, Roche, Ascensia Diabetes Care and Dexcom.
China Cardiac Surgery Instruments Market Analysis
The China Cardiac Surgery Instruments Market is expected to witness growth from $166 Mn in 2022 to $310 Mn in 2030 with a CAGR of 8.10% for the forecasted year 2022-2030. In China, due to rising disposable income, more people in China can now access better healthcare services like cardiac surgeries. This has increased demand for cardiac surgery equipment, providing manufacturers with new business opportunities. The market is segmented by type, application and by end user. Some key players in this market include Lepu Medical Technology, MicroPort, LivaNova, B. Braun, Medline Industries, KLS Martin, and STILLE.
China Cardiovascular Diseases Therapeutics Market Analysis
China's cardiovascular disease therapeutics market is expected to witness growth from $13.07 Bn in 2022 to $25.52 Bn in 2030 with a CAGR of 8.72% for the year 2022-30. The shifting lifestyle modifications in China have led to an increase in the prevalence of cardiovascular diseases, therefore, driving the growth of the market. The China cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Lanrui Boyan Medical, Beijing Handian Pharmacy, and AstraZeneca are the major players in the China cardiovascular disease therapeutics market.
China Healthcare Insurance Market Analysis
The China healthcare insurance market is projected to grow from $162.88 Bn in 2022 to $326.94 Bn by 2030, registering a CAGR of 9.1% during the forecast period of 2022 - 2030. The main factors driving the growth would be increasing health insurance premiums, growing awareness of health risks and rising medical costs. The market is segmented by component, the provider, coverage, health insurance plans and end-user. Some major players include Ping and Insurance, China Life Insurance, People’s Insurance, China Pacific Insurance and New China Life Insurance.
China Healthcare Claims Management Market Analysis
The China healthcare claims management market is projected to grow from $2.15 Bn in 2022 to $12.71 Bn by 2030, registering a CAGR of 24.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be the growing adoption of digital healthcare, increasing healthcare fraud, government initiatives and increasing healthcare spending. The market is segmented by component, type, delivery mode and by end-user. Some of the major players include Ping a Healthcare, China Pacific Insurance, Cognizant, Allianz and Cigna.
China Diagnostic Imaging Services Market
The China Diagnostic Imaging Services market size was valued at $42 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.9 % from 2022 to 2030 and will reach $61.58 Bn in 2030. The market is segmented by product, application, and end user. The China Diagnostic Imaging Services market will grow as the development of new 3D printing materials and techniques has led to the production of more complex and customizable medical devices. The key market players are Canon Medical Systems Corporation, Carestream Health Inc., Esaote SpA, FUJIFILM Holdings Corporation, and GE Healthcare.
China Oncology Clinical Trials Market Analysis
China's oncology clinical trials market is projected to grow from $1.02 Bn in 2022 to $1.75 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the country and efforts to promote research, collaboration, and innovation. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Jiangsu Hengrui Pharmaceutical & Sino Biopharmaceutical.
China Diabetes Drugs Market Analysis
The China diabetes drugs market size was valued at $4.96 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $8.9 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The China diabetes drug market will grow because China is the country with the largest population of people with diabetes in the world. The key market players are Gan & Lee Pharmaceuticals (CHN), Tonghua Dongbao Pharmaceutical (CHN), Jiangsu Hengrui Medicine (CHN), and others.
China Alexipharmic Drugs Market Analysis
China's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 6.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The China Alexipharmic Drugs market will grow because the Chinese government and healthcare providers are increasing their efforts to raise public awareness about poisoning and the availability of antidotes. The key market players are Beijing Kawin Technology Share-Holding (CHN), Yino Pharma Limited (CHN), and others.
China Neurology Clinical Trials Market Analysis
The China Neurology Clinical Trials market is projected to grow from $420.4 Mn in 2022 to $722.4 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. The market will be driven by the country's increasing incidence of neurological disorders and pharmaceutical firms boosting their investments in R&D. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer, Novartis, Shanghai Green Valley Pharmaceuticals & Jiangsu Hengrui Medicine.
China Teleradiology Market Analysis
The China Teleradiology market size was valued at $191 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 12.20% from 2022 to 2030 and will reach $ 514 Mn in 2030. The market is segmented by application, modality, technology solutions, and end user. The China teleradiology market will grow due to Increasing demand for remote radiology services. The key market players are United Imaging Healthcare (UIH), AliHealth, Nanjing Remote Medical Imaging (NRMI), Beijing Deepwise & League of PHD Technology (DL), Yitu Healthcare, and others.
China Alzheimer’s Disease Drugs Market Analysis
The China Alzheimer’s Disease Drugs market was valued at $1.24 Bn in 2022 and is estimated to expand at a CAGR of 9.42% from 2022-30 and will reach $2.64 Bn in 2030. One of the main reasons propelling the growth of this market is government support, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Shanghai Green Valley Pharmaceutica, Eisai Co., Eli Lilly and Company, H. Lundbeck A/S, Johnson and Johnson, Hengrui Medicine Co, Jiangsu Hengrui, Novartis AG, Chongqing Zhifei Biological Products, Pfizer and CSPC Pharmaceutical Group among others.
China Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the China infectious disease therapeutics market will reach a value of $15.19 Bn from $9.64 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030. Infectious Disease Therapeutics in China is dominated by a few domestic pharmaceutical companies such as WuXi Biologics, Fosun Pharma and CanSino Biologics. The infectious disease therapeutics market in China is segmented into different therapeutic areas and different treatment types. The major factors affecting the China infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of China.
China Clinical Diagnostics Market Analysis
China's clinical diagnostic market was valued at $5.5 Bn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022-30 and will reach $9.9 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic disease and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Abbott, BD, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, Siemens AG, Hologic, Qiagen NV, Quest Diagnostics, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Sysmex, Mindray, Shanghai Fosun Pharmaceutical Group, Guangzhou Wondfo Biotech, Beijing Leadman Biochemistry Co. and others.
China Artificial Intelligence (AI) in Diagnostics Market Analysis
China's Artificial Intelligence (AI) in the Diagnostics market is projected to grow from $0.08 Bn in 2022 to $0.97 Bn by 2030, registering a CAGR of 36.5% during the forecast period of 2022 - 2030. The market will be driven by the growing population and the government's strong support for the development and deployment of AI technology. The market is segmented by component & by diagnosis. Some of the major players include IBM Watson Health, Siemens Healthineers & Infervision.
China Palliative Care Market Analysis
The China Palliative care market is projected to grow from $1.05 Bn in 2022 to $2.17 Bn by 2030, registering a CAGR of 9.5% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, the rising prevalence of chronic diseases, increasing awareness and government support. The market is segmented by service type and by the end user. Some of the major players include Beijing Haidian Hospital, Fudan University Shanghai Cancer Center, Shanghai Children’s Medical Center and Jigan Temple Community Hospital.
China Robotic Surgery Services Market Analysis
The China Robotic Surgery Service market size was valued at $345 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.8% % from 2022 to 2030 and will reach $1564 Mn in 2030. The robotic surgery service market will grow due to increasing demand for minimally invasive procedures, advancements in technology, and growing prosperity in the country. The market is segmented by product and service type, application type, and end user. Some of the major players are Lingraphica (CHN), Shuanglin Group (CHN), Mirobot (CHN), and others
China Home Healthcare Market Analysis
The China home healthcare market was valued at $29.15 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.43% from 2022 to 2030 and will reach $59.94 Bn in 2030. One of the main reasons propelling the growth of this market is the rising number of the elderly population and changing lifestyles. The market is segmented by equipment outlook and by services. Some key players in this market are WeDoctor, AliHealth, Haodaifu, JD Health, and iKang Healthcare Group Guahao.
China Rheumatology Drugs Market Analysis
The China Rheumatology Drugs Market is projected to grow from $4.908 Bn in 2022 to $6.873 Bn by 2030, registering a CAGR of 4.30% during the forecast period of 2022-2030. The most commonly used drugs in the treatment of rheumatic diseases include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic agents. There are a number of domestic pharmaceutical companies in China that are actively involved in the rheumatology drugs market. These companies include China National Biotec Group, Fosun Pharma, and Jiangsu Hengrui Medicine
China Cancer Pain Management Market Analysis
China's Cancer Pain Management market is projected to grow from $524.13 Mn in 2022 to $887.17 Mn by 2030, registering a CAGR of 6.8% during the forecast period of 2022 - 2030. The main factors driving the growth would be an increase in cancer incidences, growing healthcare expenditure, and an aging population. The market is segmented by drug type and by disease. Some of the major players include Aoxing Pharmaceutical (CHN), Jiangsu Hengrui Medicine (CHN), Hisamitsu Pharmaceutical, Mundipharma, Pfizer, and Teva Pharmaceuticals.
